Who is sponsoring NCT03455777?

NCT03455777 is sponsored by Akcea Therapeutics.

What condition does NCT03455777 study?

NCT03455777 studies Homozygous Familial Hypercholesterolemia.

What drugs are being tested in NCT03455777?

Interventions: AKCEA-ANGPTL3-LRX.

What is the status of NCT03455777?

NCT03455777 is currently WITHDRAWN.

Last reviewed 2018-12-03 · How we verify

Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)

NCT03455777 PHASE2 WITHDRAWN

This is a single center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3- LRX for reduction of low density lipoprotein cholesterol (LDL-C) levels in patients with Homozygous Familial Hypercholesterolemia (HoFH).

Details

Lead sponsor	Akcea Therapeutics
Phase	PHASE2
Status	WITHDRAWN
Start date	Thu Apr 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Dec 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Homozygous Familial Hypercholesterolemia

Interventions

AKCEA-ANGPTL3-LRX

Countries

Canada